Work with Esteban Terzo | NotedSource
Strategic thinker and cross-functional communicator
showcasing nearly 6 years of biotech industry experience
leading projects as a specialist in early drug discovery,
platform development, and oncology. Proven track record of
establishing research laboratories, conceiving and
executing cell-based assays, leading external projects in
collaboration with CROs and academic partners. Passionate
about mentoring and enabling opportunities for the next
generation of scientists. Committed to finding solutions
to complex challenges and seeking new ways to push the
boundaries of discovery.
https://cv.notedsource.io/me/QZR7N87L
Esteban Terzo
Principal Scientist, Eloxx Pharmaceuticals
Research Expertise
Cell Biology
Oncology
Cancer Research
Pulmonary and Respiratory Medicine
Genetics
Genetics (clinical)
Immunology and Allergy
Immunology
Molecular Biology
Drug Discovery
Molecular Medicine
About
Strategic thinker and cross-functional
communicator showcasing nearly 6 years of
biotech industry experience leading projects
as a specialist in early drug discovery,
platform development, and oncology. Proven
track record of establishing research
laboratories, conceiving and executing
cell-based assays, leading external projects
in collaboration with CROs and academic
partners. Passionate about mentoring and
enabling opportunities for the next generation
of scientists. Committed to finding solutions
to complex challenges and seeking new ways to
push the boundaries of discovery.
Legacy Map
Full ViewPublications
A Novel Class of Ribosome Modulating
Agents Exploits Cancer Ribosome
Heterogeneity to Selectively Target the
CMS2 Subtype of Colorectal Cancer
Cancer Research Communications
2023
Data from A Novel Class of Ribosome
Modulating Agents Exploits Cancer Ribosome
Heterogeneity to Selectively Target the
CMS2 Subtype of Colorectal Cancer
Unknown Venue
2023
Data from A Novel Class of Ribosome
Modulating Agents Exploits Cancer Ribosome
Heterogeneity to Selectively Target the
CMS2 Subtype of Colorectal Cancer
Unknown Venue
2023
FIGURE 1 from A Novel Class of Ribosome
Modulating Agents Exploits Cancer Ribosome
Heterogeneity to Selectively Target the
CMS2 Subtype of Colorectal Cancer
Unknown Venue
2023
FIGURE 1 from A Novel Class of Ribosome
Modulating Agents Exploits Cancer Ribosome
Heterogeneity to Selectively Target the
CMS2 Subtype of Colorectal Cancer
Unknown Venue
2023
FIGURE 2 from A Novel Class of Ribosome
Modulating Agents Exploits Cancer Ribosome
Heterogeneity to Selectively Target the
CMS2 Subtype of Colorectal Cancer
Unknown Venue
2023
FIGURE 2 from A Novel Class of Ribosome
Modulating Agents Exploits Cancer Ribosome
Heterogeneity to Selectively Target the
CMS2 Subtype of Colorectal Cancer
Unknown Venue
2023
FIGURE 3 from A Novel Class of Ribosome
Modulating Agents Exploits Cancer Ribosome
Heterogeneity to Selectively Target the
CMS2 Subtype of Colorectal Cancer
Unknown Venue
2023
FIGURE 3 from A Novel Class of Ribosome
Modulating Agents Exploits Cancer Ribosome
Heterogeneity to Selectively Target the
CMS2 Subtype of Colorectal Cancer
Unknown Venue
2023
FIGURE 4 from A Novel Class of Ribosome
Modulating Agents Exploits Cancer Ribosome
Heterogeneity to Selectively Target the
CMS2 Subtype of Colorectal Cancer
Unknown Venue
2023
FIGURE 4 from A Novel Class of Ribosome
Modulating Agents Exploits Cancer Ribosome
Heterogeneity to Selectively Target the
CMS2 Subtype of Colorectal Cancer
Unknown Venue
2023
FIGURE 5 from A Novel Class of Ribosome
Modulating Agents Exploits Cancer Ribosome
Heterogeneity to Selectively Target the
CMS2 Subtype of Colorectal Cancer
Unknown Venue
2023
FIGURE 5 from A Novel Class of Ribosome
Modulating Agents Exploits Cancer Ribosome
Heterogeneity to Selectively Target the
CMS2 Subtype of Colorectal Cancer
Unknown Venue
2023
Figure S1 from A Novel Class of Ribosome
Modulating Agents Exploits Cancer Ribosome
Heterogeneity to Selectively Target the
CMS2 Subtype of Colorectal Cancer
Unknown Venue
2023
Figure S1 from A Novel Class of Ribosome
Modulating Agents Exploits Cancer Ribosome
Heterogeneity to Selectively Target the
CMS2 Subtype of Colorectal Cancer
Unknown Venue
2023
Figure S2 from A Novel Class of Ribosome
Modulating Agents Exploits Cancer Ribosome
Heterogeneity to Selectively Target the
CMS2 Subtype of Colorectal Cancer
Unknown Venue
2023
Figure S2 from A Novel Class of Ribosome
Modulating Agents Exploits Cancer Ribosome
Heterogeneity to Selectively Target the
CMS2 Subtype of Colorectal Cancer
Unknown Venue
2023
Figure S3 from A Novel Class of Ribosome
Modulating Agents Exploits Cancer Ribosome
Heterogeneity to Selectively Target the
CMS2 Subtype of Colorectal Cancer
Unknown Venue
2023
Figure S3 from A Novel Class of Ribosome
Modulating Agents Exploits Cancer Ribosome
Heterogeneity to Selectively Target the
CMS2 Subtype of Colorectal Cancer
Unknown Venue
2023
Supplementary Data 1 from A Novel Class of
Ribosome Modulating Agents Exploits Cancer
Ribosome Heterogeneity to Selectively
Target the CMS2 Subtype of Colorectal
Cancer
Unknown Venue
2023
Supplementary Data 1 from A Novel Class of
Ribosome Modulating Agents Exploits Cancer
Ribosome Heterogeneity to Selectively
Target the CMS2 Subtype of Colorectal
Cancer
Unknown Venue
2023
Supplementary Methods 1 from A Novel Class
of Ribosome Modulating Agents Exploits
Cancer Ribosome Heterogeneity to
Selectively Target the CMS2 Subtype of
Colorectal Cancer
Unknown Venue
2023
Supplementary Methods 1 from A Novel Class
of Ribosome Modulating Agents Exploits
Cancer Ribosome Heterogeneity to
Selectively Target the CMS2 Subtype of
Colorectal Cancer
Unknown Venue
2023
Supplementary Table 1 from A Novel Class
of Ribosome Modulating Agents Exploits
Cancer Ribosome Heterogeneity to
Selectively Target the CMS2 Subtype of
Colorectal Cancer
Unknown Venue
2023
Supplementary Table 1 from A Novel Class
of Ribosome Modulating Agents Exploits
Cancer Ribosome Heterogeneity to
Selectively Target the CMS2 Subtype of
Colorectal Cancer
Unknown Venue
2023
TABLE 1 from A Novel Class of Ribosome
Modulating Agents Exploits Cancer Ribosome
Heterogeneity to Selectively Target the
CMS2 Subtype of Colorectal Cancer
Unknown Venue
2023
TABLE 1 from A Novel Class of Ribosome
Modulating Agents Exploits Cancer Ribosome
Heterogeneity to Selectively Target the
CMS2 Subtype of Colorectal Cancer
Unknown Venue
2023
Data from A novel class of Ribosome
Modulating Agents (RMAs) exploits cancer
ribosome heterogeneity to selectively
target the CMS2 subtype of colorectal
cancer
Unknown Venue
2023
Figure S1 from A novel class of Ribosome
Modulating Agents (RMAs) exploits cancer
ribosome heterogeneity to selectively
target the CMS2 subtype of colorectal
cancer
Unknown Venue
2023
Figure S1 from A novel class of Ribosome
Modulating Agents (RMAs) exploits cancer
ribosome heterogeneity to selectively
target the CMS2 subtype of colorectal
cancer
Unknown Venue
2023
Figure S2 from A novel class of Ribosome
Modulating Agents (RMAs) exploits cancer
ribosome heterogeneity to selectively
target the CMS2 subtype of colorectal
cancer
Unknown Venue
2023
Figure S2 from A novel class of Ribosome
Modulating Agents (RMAs) exploits cancer
ribosome heterogeneity to selectively
target the CMS2 subtype of colorectal
cancer
Unknown Venue
2023
Figure S3 from A novel class of Ribosome
Modulating Agents (RMAs) exploits cancer
ribosome heterogeneity to selectively
target the CMS2 subtype of colorectal
cancer
Unknown Venue
2023
Figure S3 from A novel class of Ribosome
Modulating Agents (RMAs) exploits cancer
ribosome heterogeneity to selectively
target the CMS2 subtype of colorectal
cancer
Unknown Venue
2023
Supplementary Data 1 from A novel class of
Ribosome Modulating Agents (RMAs) exploits
cancer ribosome heterogeneity to
selectively target the CMS2 subtype of
colorectal cancer
Unknown Venue
2023
Supplementary Data 1 from A novel class of
Ribosome Modulating Agents (RMAs) exploits
cancer ribosome heterogeneity to
selectively target the CMS2 subtype of
colorectal cancer
Unknown Venue
2023
Supplementary Methods 1 from A novel class
of Ribosome Modulating Agents (RMAs)
exploits cancer ribosome heterogeneity to
selectively target the CMS2 subtype of
colorectal cancer
Unknown Venue
2023
Supplementary Methods 1 from A novel class
of Ribosome Modulating Agents (RMAs)
exploits cancer ribosome heterogeneity to
selectively target the CMS2 subtype of
colorectal cancer
Unknown Venue
2023
Supplementary Table 1 from A novel class
of Ribosome Modulating Agents (RMAs)
exploits cancer ribosome heterogeneity to
selectively target the CMS2 subtype of
colorectal cancer
Unknown Venue
2023
Supplementary Table 1 from A novel class
of Ribosome Modulating Agents (RMAs)
exploits cancer ribosome heterogeneity to
selectively target the CMS2 subtype of
colorectal cancer
Unknown Venue
2023
Concentrating pre-mRNA processing factors
in the histone locus body facilitates
efficient histone mRNA biogenesis
Journal of Cell Biology
2016
SETD2 Haploinsufficiency for
Microtubule Methylation Is an Early Driver
of Genomic Instability in Renal Cell
Carcinoma
Cancer Research
2018
KLF6-SV1 Is a Novel Antiapoptotic Protein
That Targets the BH3-Only Protein NOXA for
Degradation and Whose Inhibition Extends
Survival in an Ovarian Cancer Model
Cancer Research
2009
Targeted reduction of KLF6-SV1 restores
chemotherapy sensitivity in resistant lung
adenocarcinoma
Lung Cancer
2009
Primate Genome Gain and Loss: A Bone
Dysplasia, Muscular Dystrophy, and Bone
Cancer Syndrome Resulting from Mutated
Retroviral-Derived MTAP Transcripts
The American Journal of Human
Genetics
2012
Distinct self-interaction domains promote
Multi Sex Combs accumulation in and
formation of theDrosophilahistone
locus body
Molecular Biology of the Cell
2015
Methylated α-tubulin antibodies recognize
a new microtubule modification on mitotic
microtubules
mAbs
2016
SETD2 loss sensitizes cells to
PI3Kβ and AKT inhibition
Oncotarget
2019
Molecular cloning of multiple forms of the
ovine B7-2 (CD86) costimulatory molecule
Veterinary Immunology and
Immunopathology
2006
Molecular cloning and mRNA
tissue-expression of two isoforms of the
ovine costimulatory molecule CD80 (B7-1)
Veterinary Immunology and
Immunopathology
2005
CREBBP/EP300 acetyltransferase inhibition
disrupts FOXA1-bound enhancers to inhibit
the proliferation of ER+ breast cancer
cells
PLOS ONE
2022
Abstract 4722: Efficacy of a novel
EP300/CBP histone acetyltransferase
inhibitor in hormone responsive breast
cancer
Cancer Research
2019
Novel read through agent: ZKN-0013
demonstrates efficacy in APCmin model of
familial adenomatous polyposis
Journal of Molecular Medicine
2023
A novel class of Ribosome Modulating
Agents (RMAs) target MYC driven SCLC and
synergize with DNA intercalating agents
European Journal of Cancer
2022
A novel class of Ribosome Modulating
Agents (RMAs) targets ribosome
heterogeneity in a subset of colorectal
cancers
European Journal of Cancer
2022
Correction: SETD2 loss sensitizes
cells to PI3Kβ and AKT inhibition
Oncotarget
2019
Abstract 1942: Synthetic lethal
interaction between SETD2 loss and
inhibition of PI3Kβ in clear cell renal
cell carcinoma (ccRCC)
Cancer Research
2018
Abstract B059: SETD2-PI3Kβ synthetic
lethality
Molecular Cancer Therapeutics
2018
Abstract 3071: Exploring the molecular
mechanism underlying SETD2-PI3Kβ
synthetic-lethal interaction in renal cell
carcinoma (RCC)
Cancer Research
2017
Abstract LB-89: Discovery and
characterization of novel MTAP splice
variants resulting in a hereditary form of
osteosarcoma and demonstration of their
dysregulation in sporadic forms of this
cancer
Cancer Research
2012
Data from KLF6-SV1 Is a Novel
Antiapoptotic Protein That Targets the
BH3-Only Protein NOXA for Degradation and
Whose Inhibition Extends Survival in an
Ovarian Cancer Model
Unknown Venue
2023
Education
University of North Carolina at Chapel Hill
Ph.D., Genetics and Molecular Biology / December, 2015
Chapel Hill, North Carolina, United
States of America
Experience
Eloxx Pharmaceuticals
Join Esteban on NotedSource!
Join Now
At NotedSource, we believe that professors, post-docs, scientists and other researchers have deep, untapped knowledge and expertise that can be leveraged to drive innovation within companies. NotedSource is committed to bridging the gap between academia and industry by providing a platform for collaboration with industry and networking with other researchers.
For industry, NotedSource identifies the right academic experts in 24 hours to help organizations build and grow. With a platform of thousands of knowledgeable PhDs, scientists, and industry experts, NotedSource makes connecting and collaborating easy.
For academic researchers such as professors, post-docs, and Ph.D.s, NotedSource provides tools to discover and connect to your colleagues with messaging and news feeds, in addition to the opportunity to be paid for your collaboration with vetted partners.
Expert Institutions
Proudly trusted by
